



## Supplementary figures




**Figure S1** Diagram of experimental methods. Graphical representation of methods, including 2-acetylaminofluorine pellet implantation, two-thirds partial hepatectomy, injections of  $\gamma$ -secretase inhibitor, and dates of animal sacrifice.




**Figure S2** Control immunohistochemistry for both treatment groups. Immunohistochemical analysis of control samples for both treatment groups (2AAF-PH alone (left panels) as well as in combination with GSI XX treatment (right panels). **A**) and **B**) hematoxylin and eosin; **C**) and **D**) OV-6; **E**) and **F**) AFP; **G**) and **H**) Ki67; **I**) and **J**) CYP3A2. The hematoxylin and eosin staining compares sections from normal liver (**A**) with vehicle-only treated liver (**B**). In the case of both OV-6 and AFP, there is no (or minimal) expression seen for both control samples as expected. Controls for both treatment groups showed just a small bit of positivity for Ki67, showing that only a very small percentage of cells are proliferating at this stage of regeneration. In the case of CYP3A2, a mature hepatocyte marker, there is robust expression by a majority of hepatocytes in both control groups, indicative of cellular maturity as well as functionality. **A–J** 200 $\times$ .

**Abbreviations:** GSI XX,  $\gamma$ -secretase inhibitor; PH, partial hepatectomy; 2AAF-PH, 2-acetylaminofluorine implantation followed by 70% surgical resection of the liver; AFP, alpha-fetoprotein.



**Figure S3** Immunohistochemistry for HGF in both treatment groups. Immunohistochemical analysis of control samples for both treatment groups (2AAF-PH alone (left panels) as well as in combination with GSI XX treatment (right panels). **A**) and **B**) Control; **C**) and **D**) Day 11 post-PH; **E**) and **F**) Day 22 post-PH. There appears to be no significant differences between the two groups at each individual time point. **A–F** 200 $\times$ .

**Abbreviations:** GSI XX,  $\gamma$ -secretase inhibitor; PH, partial hepatectomy; 2AAF-PH, 2-acetylaminofluorine implantation followed by 70% surgical resection of the liver; HGF, hepatic growth factor.



**Figure S4** Antibody isotype controls. Immunohistochemical analysis of liver samples to determine nonspecific antibody binding. Liver sections utilized were from 2AAF-PH treated animals at day 11. **A**) Mouse (OV-6, Ki67) **B**) Rabbit (AFP, CYP3A2). **A–B** 200 $\times$ .

## Hepatic Medicine: Evidence and Research

## Publish your work in this journal

Hepatic Medicine: Evidence and Research is an international, peer-reviewed, open access journal covering all aspects of adult and pediatric hepatology in the clinic and laboratory including the following topics: Pathology, pathophysiology of hepatic disease; Investigation and treatment of hepatic disease; Pharmacology of drugs used for

Submit your manuscript here: <http://www.dovepress.com/hepatic-medicine-evidence-and-research-journal>

Dovepress

the treatment of hepatic disease. Issues of patient safety and quality of care will also be considered. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.